- Home
- Publications
- Publication Search
- Publication Details
Title
Drug discovery targeting the mTOR pathway
Authors
Keywords
-
Journal
CLINICAL SCIENCE
Volume 132, Issue 5, Pages 543-568
Publisher
Portland Press Ltd.
Online
2018-03-10
DOI
10.1042/cs20171158
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Connecting chaperone-mediated autophagy dysfunction to cellular senescence
- (2018) Daniel Moreno-Blas et al. AGEING RESEARCH REVIEWS
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- (2018) David Schiff et al. CANCER
- mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
- (2018) Amin Ardestani et al. Cell Metabolism
- Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
- (2018) Glenn J. Hanna et al. CLINICAL CANCER RESEARCH
- FLCN : The causative gene for Birt-Hogg-Dubé syndrome
- (2018) Laura S. Schmidt et al. GENE
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
- (2017) Christophe Massard et al. EUROPEAN JOURNAL OF CANCER
- Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma
- (2017) P. Penttilä et al. EUROPEAN JOURNAL OF CANCER
- Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
- (2017) Hui Li et al. HEPATOLOGY
- Tuberous sclerosis complex: Recent advances in manifestations and therapy
- (2017) Mari Wataya-Kaneda et al. INTERNATIONAL JOURNAL OF UROLOGY
- Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
- (2017) Zongbi Yi et al. Journal of Breast Cancer
- PtdIns3P controls mTORC1 signaling through lysosomal positioning
- (2017) Zhi Hong et al. JOURNAL OF CELL BIOLOGY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation
- (2017) Juan Francisco Rodríguez-Moreno et al. Journal of the National Comprehensive Cancer Network
- Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial
- (2017) Hope S Rugo et al. LANCET ONCOLOGY
- Targeting metabolism in cellular senescence, a role for intervention
- (2017) Timothy Nacarelli et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph + and Ph-like B-ALL
- (2017) Thanh-Trang T. Vo et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines
- (2017) Giovanni Vitale et al. Molecular Oncology
- Clonal evolution in leukemia
- (2017) Adolfo A Ferrando et al. NATURE MEDICINE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
- (2017) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- (2017) T Fujishita et al. ONCOGENE
- Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
- (2017) Ramon Salazar et al. ONCOLOGIST
- mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells
- (2017) Walaa Eid et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
- (2017) Zev A. Wainberg et al. Targeted Oncology
- Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
- (2017) Dearbhaile C. Collins et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
- (2017) Jordi Rodon et al. Cancer Discovery
- Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
- (2017) Eirini Pectasides et al. Cancer Discovery
- HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
- (2017) Eva Juengel et al. Oncotarget
- Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation
- (2017) Teun van Gelder et al. Transplantation Reviews
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
- (2017) Zijun Y. Xu-Monette et al. Frontiers in Immunology
- Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
- (2017) Paul Hofman Cancers
- PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
- (2017) Michele Milella et al. Scientific Reports
- TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia
- (2016) Irene M. Ghobrial et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rag GTPase in amino acid signaling
- (2016) Joungmok Kim et al. AMINO ACIDS
- Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature
- (2016) KRISTEN D STARBUCK et al. ANTICANCER RESEARCH
- Monitoring of CD8(+) T-cell Activity in mTOR Inhibitor-treated Cancer Patients for Successful Immunotherapy
- (2016) Alireza Bolourian et al. ARCHIVES OF MEDICAL RESEARCH
- Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer
- (2016) James A. McCubrey et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
- (2016) Emmanuel Seront et al. BJU INTERNATIONAL
- Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
- (2016) Timon Vandamme et al. BRITISH JOURNAL OF CANCER
- New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease
- (2016) Mathias Lutz et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders
- (2016) Camilla Evangelisti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation
- (2016) Matthias Waldner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The therapeutic potential of mTOR inhibitors in breast cancer
- (2016) Linda S. Steelman et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
- (2016) Wei Wei et al. CANCER CELL
- Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
- (2016) Yukiyoshi Hirayama et al. CANCER SCIENCE
- The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging
- (2016) Brian K. Kennedy et al. Cell Metabolism
- Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
- (2016) Jennifer S. Carew et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies
- (2016) Antonella Tramutola et al. Expert Review of Neurotherapeutics
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- The TORC1-activated Proteins, p70S6K and GRB10, Regulate IL-4 Signaling and M2 Macrophage Polarization by Modulating Phosphorylation of Insulin Receptor Substrate-2
- (2016) Kristi J. Warren et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances
- (2016) Xianwei Chen et al. Journal of Proteomics
- Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
- (2016) Jacqueline A French et al. LANCET
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide
- (2016) Akinobu Matsumoto et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Mechanism of arginine sensing by CASTOR1 upstream of mTORC1
- (2016) Robert A. Saxton et al. NATURE
- The mTOR signalling cascade: paving new roads to cure neurological disease
- (2016) Peter B. Crino Nature Reviews Neurology
- mTORC1 and mTORC2 in cancer and the tumor microenvironment
- (2016) L C Kim et al. ONCOGENE
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus
- (2016) Marianne Pavel et al. Targeted Oncology
- Biochemical Basis of Sestrin Physiological Activities
- (2016) Allison Ho et al. TRENDS IN BIOCHEMICAL SCIENCES
- Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling
- (2016) Lili Guo et al. TUMOR BIOLOGY
- Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
- (2016) XIAOYU YANG et al. Oncology Letters
- Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review
- (2016) Ezequiel Flechter et al. Oncology Letters
- CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway
- (2016) Qiuyuan Wen et al. Oncotarget
- Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies
- (2016) Antonella Tramutola et al. Expert Review of Neurotherapeutics
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
- (2016) Douglas E. Peterson et al. Cancer Medicine
- Therapeutic Targeting of Autophagy
- (2016) Christina G. Towers et al. EBioMedicine
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening
- (2015) Joanna Trelinska et al. ANTI-CANCER DRUGS
- Signalling to eIF4E in cancer
- (2015) N. Siddiqui et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Autophagy in acute leukemias: A double-edged sword with important therapeutic implications
- (2015) Cecilia Evangelisti et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data
- (2015) Karen A. Ryall et al. BIOINFORMATICS
- Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
- (2015) Kimberly Blackwell et al. BREAST CANCER RESEARCH AND TREATMENT
- Potential therapeutic effects of mTOR inhibition in atherosclerosis
- (2015) Ammar Kurdi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders
- (2015) Kenneth Maiese BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Autophagy in malignant transformation and cancer progression
- (2015) L. Galluzzi et al. EMBO JOURNAL
- mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
- (2015) Feng Wei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
- (2015) Kazuhiro Tanaka et al. JOURNAL OF CLINICAL INVESTIGATION
- The S6K protein family in health and disease
- (2015) Mariana R. Tavares et al. LIFE SCIENCES
- Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
- (2015) H. P. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2
- (2015) Christl Gaubitz et al. MOLECULAR CELL
- Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy
- (2015) Esperanza Arias et al. MOLECULAR CELL
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR in Brain Physiology and Pathologies
- (2015) Joël Bockaert et al. PHYSIOLOGICAL REVIEWS
- mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy
- (2015) Jinghui Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The role of mTOR in lipid homeostasis and diabetes progression
- (2015) Partha Chakrabarti et al. Current Opinion in Endocrinology Diabetes and Obesity
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
- (2015) Giuseppe Bronte et al. Oncotarget
- Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients
- (2015) Mau-Shin Chi et al. Oncotarget
- The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
- (2015) Carolina Simioni et al. Oncotarget
- Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
- (2015) Kwan-Hwa Chi et al. Oncotarget
- Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells
- (2015) Hyung-Ok Lee et al. PLoS One
- Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
- (2015) Alberto M. Martelli et al. Oncotarget
- Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades
- (2015) James Andrew McCubrey et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
- (2014) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
- (2014) I. Treilleux et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Combined MTOR and autophagy inhibition
- (2014) Reshma Rangwala et al. Autophagy
- Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art
- (2014) J. Michael Randall et al. CANCER AND METASTASIS REVIEWS
- FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway
- (2014) Aifu Lin et al. CANCER RESEARCH
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors
- (2014) Ozgur Sahin et al. CELL RESEARCH
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- PIKKs — the solenoid nest where partners and kinases meet
- (2014) Domagoj Baretić et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation
- (2014) Yukiko Hasumi et al. HUMAN MOLECULAR GENETICS
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
- (2014) David Neal Franz et al. LANCET ONCOLOGY
- Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
- (2014) D. Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- The structural basis for mTOR function
- (2014) Domagoj Baretić et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Regulation of mTORC1 by amino acids
- (2014) Liron Bar-Peled et al. TRENDS IN CELL BIOLOGY
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
- (2013) E Seront et al. BRITISH JOURNAL OF CANCER
- Metabolic complications with the use of mTOR inhibitors for cancer therapy
- (2013) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- p53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA Damage
- (2013) Maren Cam et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
- (2013) Claire L. Cope et al. JOURNAL OF CELL SCIENCE
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
- (2013) Bing Li et al. LUNG CANCER
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
- (2013) D. A. Krueger et al. NEUROLOGY
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- (2013) G S Ducker et al. ONCOGENE
- Pancreatic tumours escape from translational control through 4E-BP1 loss
- (2013) Y Martineau et al. ONCOGENE
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma
- (2013) Xiaoqi Xie et al. PLoS One
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- (2013) H. Ebi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
- (2013) L. Bar-Peled et al. SCIENCE
- Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells
- (2013) P. Casado et al. Science Signaling
- eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
- (2012) T. Alain et al. CANCER RESEARCH
- Ragulator Is a GEF for the Rag GTPases that Signal Amino Acid Levels to mTORC1
- (2012) Liron Bar-Peled et al. CELL
- Functional Assessment ofTSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex
- (2012) Marianne Hoogeveen-Westerveld et al. HUMAN MUTATION
- Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
- (2012) Mark A. Dickson et al. INTERNATIONAL JOURNAL OF CANCER
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms
- (2012) Ludovica Ciuffreda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Combined therapeutic application of mTOR inhibitor and vitamin D3 for inflammatory bone destruction of rheumatoid arthritis
- (2012) Tae-Hwan Kim et al. MEDICAL HYPOTHESES
- mTOR inhibition with rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
- (2012) Maria J. Pereira et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
- (2012) Kevin Bray et al. PLoS One
- Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
- (2012) D. W. Lamming et al. SCIENCE
- Genome Sequencing Identifies a Basis for Everolimus Sensitivity
- (2012) G. Iyer et al. SCIENCE
- Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
- (2012) Constantine Gennatas et al. World Journal of Surgical Oncology
- Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney
- (2011) Laura R. Pearce et al. BIOCHEMICAL JOURNAL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- The mTOR (Mammalian Target of Rapamycin) Kinase Maintains Integrity of mTOR Complex 2
- (2011) Chien-Hung Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
- (2011) C Evangelisti et al. LEUKEMIA
- Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia
- (2011) N. C. Wolff et al. MOLECULAR AND CELLULAR BIOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTORC1 Senses Lysosomal Amino Acids Through an Inside-Out Mechanism That Requires the Vacuolar H+-ATPase
- (2011) R. Zoncu et al. SCIENCE
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- The ATM protein kinase and cellular redox signaling: beyond the DNA damage response
- (2011) Scott Ditch et al. TRENDS IN BIOCHEMICAL SCIENCES
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Insulin-induced serine phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of Ser675 and Ser907
- (2010) Louise Fritsche et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
- (2010) A. Italiano et al. ANNALS OF ONCOLOGY
- Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
- (2010) Sven A. Lang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling
- (2010) Ming Li et al. CELLULAR SIGNALLING
- Requirement of the mTOR Kinase for the Regulation of Maf1 Phosphorylation and Control of RNA Polymerase III-dependent Transcription in Cancer Cells
- (2010) Boris Shor et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
- (2010) Takeshi Kaizuka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
- (2010) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic targeting of mTOR in tuberous sclerosis
- (2009) Julian R. Sampson BIOCHEMICAL SOCIETY TRANSACTIONS
- Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
- (2009) F. Chiarini et al. CANCER RESEARCH
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligase
- (2009) Samiksha Katiyar et al. EMBO REPORTS
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
- (2009) M. A. Lopez-Lago et al. MOLECULAR AND CELLULAR BIOLOGY
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2
- (2009) Y. Hasumi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Phosphorylates the ULK1-mAtg13-FIP200 Autophagy Regulatory Complex
- (2009) E. Y. Chan Science Signaling
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
- (2008) B. Shor et al. CANCER RESEARCH
- Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
- (2008) Audrey Carrière et al. CURRENT BIOLOGY
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
- (2008) Arkaitz Carracedo et al. JOURNAL OF CLINICAL INVESTIGATION
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More